Latest Advances in AML Treatment from ASCO 2025: Exploring Oral Regimens and Comparative Effectiveness
Amer Zeidan, MBBS, discusses how the future of acute myeloid leukemia (AML) treatment is shifting toward all-oral combination therapies like decitabine-cedazuridine plus venetoclax, which could become a new standard of care by reducing patient clinic burden while maintaining efficacy comparable to current intravenous regimens.
Episodes
June 30th 2025EP. 1: Unmet Needs and Emerging Trends in AML: ASCO 2025 Insights
A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 mutations and MECOM rearrangements, while emerging trends focus on combination therapies (doublets, triplets, quadruplets), the shift toward more convenient oral therapies, increased emphasis on minimal residual disease negativity as an end point, and expanded transplant eligibility for older patients aged into their mid to late 70s.
